BR112022023486A2 - Tratamento para amiloidose - Google Patents

Tratamento para amiloidose

Info

Publication number
BR112022023486A2
BR112022023486A2 BR112022023486A BR112022023486A BR112022023486A2 BR 112022023486 A2 BR112022023486 A2 BR 112022023486A2 BR 112022023486 A BR112022023486 A BR 112022023486A BR 112022023486 A BR112022023486 A BR 112022023486A BR 112022023486 A2 BR112022023486 A2 BR 112022023486A2
Authority
BR
Brazil
Prior art keywords
amyloidosis
treatment
formula
compounds
amylodosis
Prior art date
Application number
BR112022023486A
Other languages
English (en)
Portuguese (pt)
Inventor
Duane Bunker Kevin
Abdi Samatar Ahmed
Robert Pinchman Joseph
Qinhua Huang Peter
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of BR112022023486A2 publication Critical patent/BR112022023486A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05Dipeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07Tetrapeptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • External Artificial Organs (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112022023486A 2020-05-19 2021-05-17 Tratamento para amiloidose BR112022023486A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063027194P 2020-05-19 2020-05-19
PCT/US2021/032808 WO2021236543A1 (en) 2020-05-19 2021-05-17 Treatment for amyloidosis

Publications (1)

Publication Number Publication Date
BR112022023486A2 true BR112022023486A2 (pt) 2023-01-10

Family

ID=78708017

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022023486A BR112022023486A2 (pt) 2020-05-19 2021-05-17 Tratamento para amiloidose

Country Status (12)

Country Link
US (1) US20230210846A1 (enExample)
EP (1) EP4138837A4 (enExample)
JP (1) JP2023527741A (enExample)
KR (1) KR20230013102A (enExample)
CN (1) CN116133661A (enExample)
AU (1) AU2021273731A1 (enExample)
BR (1) BR112022023486A2 (enExample)
CA (1) CA3183746A1 (enExample)
IL (1) IL298297A (enExample)
MX (1) MX2022014468A (enExample)
TW (1) TW202207931A (enExample)
WO (1) WO2021236543A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024546584A (ja) * 2021-12-15 2024-12-26 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー Bcl-2阻害剤、wee-1阻害剤及び他の化学療法剤の三剤療法の組み合わせ

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3087261A1 (en) * 2018-01-10 2019-07-18 Recurium Ip Holdings, Llc Benzamide compounds
US20210154368A1 (en) * 2018-04-09 2021-05-27 Case Western Reserve University Bioink and crosslinkable support medium for printing
DK3774591T3 (da) * 2018-04-10 2023-03-20 Ddp Specialty Electronic Materials Us Llc Dispenser til dåse med fast ventilspindelhus
US10511808B2 (en) * 2018-04-10 2019-12-17 Facebook, Inc. Automated cinematic decisions based on descriptive models

Also Published As

Publication number Publication date
EP4138837A1 (en) 2023-03-01
CN116133661A (zh) 2023-05-16
TW202207931A (zh) 2022-03-01
EP4138837A4 (en) 2024-05-22
WO2021236543A1 (en) 2021-11-25
JP2023527741A (ja) 2023-06-30
AU2021273731A1 (en) 2022-12-15
CA3183746A1 (en) 2021-11-25
MX2022014468A (es) 2023-02-09
IL298297A (en) 2023-01-01
US20230210846A1 (en) 2023-07-06
KR20230013102A (ko) 2023-01-26

Similar Documents

Publication Publication Date Title
MX2009006846A (es) Derivados de tetraciclina para el tratamiento de infecciones bacterianas, virales y parasitarias.
GT200600432A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la beta-secretasa
BR112021022061A2 (pt) Inibidores de kcnt1 e métodos de uso
SA521430751B1 (ar) Kcnt1 مثبطات وطرق استخدامها
BR112023014973A2 (pt) Derivados de urolitina e métodos de uso dos mesmos
CY1112706T1 (el) Παραγωγα 4-βενζυλαμινο-1-καρβοξυακυλ-πιπεριδινης ως αναστολεις της cετρ, χρησιμοι για τη θεραπεια ασθενειων οπως η υπερλιπιδαιμια ή η αρτήριοσκληρωση
BRPI0606690A2 (pt) composto; uso do composto para o tratamento de uma doença ou distúrbio associado com uma atividade excessiva de bace; e composição farmacêutica
MX2021014350A (es) Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de los mismos y metodos de tratamiento con los mismos.
BR112022019041A2 (pt) Inibidores de kcnt1 e métodos de uso
ECSP21080096A (es) Composiciones y métodos para el tratamiento de enfermedades mediadas por kit y pdgfra
BR112017013768A2 (pt) composto de bipiridina, composição, seu uso e método para o controle de um artrópode nocivo".
MX2024008551A (es) Terapias de combinacion.
CY1114091T1 (el) ΠΑΡΑΓΟΝΤΕΣ ΓΙΑ ΠΡΟΛΗΨΗ ΚΑΙ ΘΕΡΑΠΕΙΑ ΔΙΑΤΑΡΑΧΩΝ ΠΟΥ ΠΕΡΙΛΑΜΒΑΝΟΥΝ ΔΙΑΦΟΡΟΠΟΙΗΣΗ ΤΩΝ ΥΠΟΔΟΧΕΩΝ RyR
BR112022020147A2 (pt) Compostos para tratar a doença de huntington
BR112018002074A2 (pt) composição, processo para a proteção de um material orgânico, uso de um composto, e, composto.
BRPI0613861B8 (pt) derivados de isoquinolona piperidinil-substituídos como inibidores de rho-cinase
EA201591918A1 (ru) Производные тамоксифена для лечения новообразований, особенно с высоким уровнем белка her2
BR112022005627A2 (pt) Composto de fórmula estrutural i ou um sal do mesmo, composição farmacêutica e uso de um composto
BR112023015210A2 (pt) Inibidores de cdk2 e métodos de uso dos mesmos
BR112022012280A2 (pt) Combinações
BR112022012281A2 (pt) Combinações
BR0207645A (pt) Compostos carbamato para utilização na prevenção ou tratamento de distúrbios neurodegenerativos
EA202190011A1 (ru) ПРОИЗВОДНЫЕ ТИОФЕНА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ЛЕЧЕНИЯ НАРУШЕНИЙ, ВЫЗВАННЫХ IgE
EA202092815A1 (ru) Новый стабилизатор длительного действия для резины и резиновая смесь для шин, содержащая указанный стабилизатор
ECSP056220A (es) Nuevos compuestos 2-piridiniletilbenzamida

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]